key: cord-0296753-230sp1bj authors: Njarekkattuvalappil, S. K.; Bhaskaran, R.; Vijaya Raj, S. R.; Jose, P.; Rafi, A. M.; Thomas, J.; Innah, S.; Raphael, L.; G, U. U.; R, P.; Valsan, C.; Kuttichira, P. title: Prospective sero surveillance among healthcare workers vaccinated with ChAdOx1 nCoV-19 Corona vaccine in a tertiary hospital of Kerala, India date: 2021-07-03 journal: nan DOI: 10.1101/2021.06.29.21259686 sha: 32657cd73072ca3fb8493163b6ce11dc537dfb37 doc_id: 296753 cord_uid: 230sp1bj Background: India started Covid-19 vaccination from January 16, 2021 after the approval of two candidate vaccines namely Covishield TM and Covaxin TM .We report antibody responses among healthcare workers following two doses of CovishieldTM vaccination in a tertiary care setting. Methods: This prospective serosurveillance study was done among healthcare workers of JMMC&RI ,vaccinated during January to March 2021. Blood samples were drawn from 170 participants after their 1st dose and from 156 participants after their 2nd dose of COVID vaccine to measure the specific antibodies against the recombinant S1 subunit of the S protein of SARS CoV 2 Results: The median level of anti SARS CoV-2 Ig G antibody 28 days after the first dose vaccination is 3.64 S/C (IQR=5.91) and 11.6 S/C (IQR= 5.97) after 14 days of second dose vaccination. Protective levels of anti SARS CoV-2 Ig G antibodies is developed by 25 participants (14.7%) after 28 days of first dose of vaccination and by 109 participants (69.9%) after 14 days of second dose. 18-44 years age group (p=0.027) and absence of comorbidities (p=0.079) are associated with protective IgG levels. Conclusions: Rise in specific Ig G is observed after vaccination. Higher antibody response is observed with younger age group and absence of comorbidities, though statistically not significant. The influence of BMI is also not significant. The COVID 19 pandemic entered a second peak in India towards early April and is now in a declining mode in all the states including Kerala. The pandemic of Coronavirus disease 2019 (COVID-19) caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has already affected more than 171 million people and caused more than 3 million deaths worldwide, as of June 04, 2021 [1] . To contain this brunt, several novel vaccines recently received an emergency use After receiving EUA, these vaccines were administered to health-care workers, front-line workers, elderly, and at-risk individuals, including people with comorbidities, in a phased roll-out [2] . The vaccination program in India started on January 16, 2021 after the approval of two candidate vaccines namely Covishield TM (ChAdOx1-nCOV or AZD1222, acquired from Oxford University Our institute also started the vaccination programme with the two dose-regimen of ChAdOx1 nCoV-19 coronavirus vaccine (Covishield TM ), given 4-6 weeks apart intramuscularly. Covishield TM is a recombinant, replication deficient, chimpanzee adenovirus vector encoding the SARS CoV-2 spike (S) glycoprotein produced in genetically modified human embryonic kidney (HEK) 293 cells. Trials have shown that the vaccine induced a clear antibody response at 28 days after the first dose, across all age groups, including the elderly [4] . As antibody levels correlate with the neutralizing antibody levels; we decided to measure the SARS-CoV-2 Ig G antibody and total antibody to estimate the immune response to the vaccine. The immune response among individuals vaccinated against SARS CoV-2 is hitherto less known. In the light of current vaccination drive by the government with frequently changing dosage intervals, it is imperative to measure the antibody responses to ascertain . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted July 3, 2021. ; https://doi.org/10.1101/2021.06.29.21259686 doi: medRxiv preprint protection from SARS CoV-2 infection among the individuals. Host factors like age, body mass index, comorbidities also determine the response to vaccines and these have also been examined. Institute is a 1600 bedded teaching hospital with around 3000 staff in the regular pay rolls, daily wagers, and workers of service contractors. The institute started vaccination of its staff with ChAdOx1 nCoV-19 coronavirus vaccine, as per the Government of India guidelines, using the vaccine supplied by the Kerala Health Services on 19 January 2021. Baseline antibody levels of individuals against SARS CoV-2, prior to vaccination, is available with us as part of the study conducted in our institute during September to December 2020 [5] . The current study is a prospective sero surveillance study initiated after obtaining the Institutional Ethics Committee approval from January 2021 to April 2021. Participants of the study were healthcare workers of JMMC & RI: (a) who have provided their prevaccination serum sample for SARS CoV-2 antibody estimation and found negative (b) who have taken the first dose of ChAdOx1 nCoV-19 Coronavirus vaccine (c) with no history or test result suggestive of Covid infection. Satisfaction of all the three criteria was essential to be part of the study. After obtaining informed consent, a self-administered questionnaire in Google forms was filled by the participant (Annexure 1). On the day of the second dose of vaccination, which ranged from 28 to 56 days after the first dose, a 5 ml blood sample was drawn by a trained phlebotomy team. Similarly, blood samples were also drawn 14 days after the 2 nd dose (i.e. 42 days after 1 st dose) from the same set of participants. A total of 170 individuals provided their blood samples after the first dose of vaccination. 14 participants were excluded from the second analysis of the study as they refused to provide consent for repeat blood samples. The blood samples collected were centrifuged and plasma separated and frozen at -20 0 Celsius for batch testing. The samples were subjected to SARS-CoV-2 Ig G and total antibody testing using the VITROS anti SARS CoV-2 Ig G/Total Chemiluminescence kit manufactured by Ortho Clinical Diagnostics, USA (OCD). Both the VITROS anti-SARS-CoV-2 Total and Ig G assays (Ortho Clinical Diagnostics) are based on CLIA using luminol-horseradish . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted July 3, 2021. ; https://doi.org/10.1101/2021.06.29.21259686 doi: medRxiv preprint peroxidase (HRP)-mediated chemiluminescence. Both assays were performed on the VITROS 3600 automated immunoassay analyzer (Ortho Clinical Diagnostics) according to the manufacturer's instructions. In these assays, the specific antibodies against the recombinant S1 subunit of the S protein of SARS-CoV-2 were automatically analyzed. Results are reported as signal/cut-off (S/C) values and as qualitative results indicating non-reactive (S/C < 1.0; negative) or reactive (S/C The study was conducted among 170 healthcare workers of different cadres who received Covishield TM vaccination. Table 1 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 3, 2021. Sub-group analysis (Table 3) . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 3, 2021. ; https://doi.org/10.1101/2021.06.29.21259686 doi: medRxiv preprint Antibody response plays a major role in developing protective immunity during SARS-CoV-2 infection [8] . Although sero-positivity based on different cut off values of I g G titres does not necessarily translate into direct protection from SARS-CoV-2 infection, it can be used as a surrogate biomarker of immunity in assessing the human humoral response to Covid-19. In this study, we assessed the humoral immune response after the first and second doses of Covishield™ vaccine in healthcare workers (HCWs) in a tertiary hospital in Kerala. The samples were subjected to SARS-CoV-2 Ig G and total antibody testing using the VITROS anti SARS CoV-2 Ig G/Total Chemi luminescence kit manufactured by Ortho Clinical Diagnostics, USA, which has already been validated to have a high specificity in detection of antibodies in convalescent plasma of Covid infected patients [9] .However, the protective levels of antibody, post vaccination has not yet been validated. Hence we followed the cut-off value of 9.5 S/C as prescribed by the manufacturer based on protective levels required for convalescent plasma [6]. It has already been proved in various studies [10] , [11] that Ig G levels following natural infection with SARS CoV-2 can persist for several months, including an ongoing study on a cohort of Belgian hospital workers, which shows persistence of Ig G till upto 199 days [12] . This principle may also be applied for antibody response following vaccine administration. From a pooled analysis of four randomized trials on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine by Voysey et al. it is already known that individuals aged 18-55 years who received a second dose vaccine more than 12 weeks after the first had antibody titres more than two-fold higher than those who received the second dose within 6 weeks of their initial vaccination [4] . In our study, among the 170 HCWs, protective antibody levels were found in 14.7% after first dose which rose to 69.9 % after the second dose of Covishield™ vaccine. Katie J Ewer et al reports an increase of spike specific IgG activity between day 28 and 56 after dosing [13] and Folegatti et al reports an increase in protective neutralizing antibody levels after second dose [14] . Our observations are in concordance with these two studies. However, an Indian study by Awadhesh et al among HCWs reports 79.3% positivity which is higher than our findings [15] . Inclusion of subjects with history of Covid-19 could be a reason to explain the faster high antibody level in this report. We . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 3, 2021. Subgroup analysis of those participants who built up protective antibody levels in our study reveals a preponderance of 18-44 years age group (p=0.027). 80% participants who developed Ig G more than 9.5 S/C following first dose vaccination and 75.2% following second dose belong to this particular age group. The majority of above 60 years age group remained to be 'low-responders' despite two The time interval between two doses of the vaccine in our study ranges from 28 to 56 days. Even though there is enough evidence to show that an increasing time interval between two doses of . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 3, 2021. ; https://doi.org/10.1101/2021.06.29.21259686 doi: medRxiv preprint Covishield™ is beneficial in building up antibody response[24], we could not observe any such significant association ( figure 3) . This might be a function of the small sample size of our study. This is a prospective serosurveillance study following up a cohort of vaccinated healthcare workers for one year. These are the preliminary results of the study. Our limitations include a small sample size and exclusion of individuals who developed Covid-19 infection before or in between vaccination. We have also not looked into cell-mediated immune responses which could augment responses against Covid-19 virus. Evidence base for optimal vaccine dosage, timings of doses, adverse events following immunization and need for booster dose remains scarce for Covid 19 vaccinations. The current study observed positive antibody response to the first dose of Covishield vaccine which is enhanced after the second dose. Antibody response in younger age groups is higher and the influence of BMI and co-morbidity is not significant. Given the current scenario in India where there is scarcity of hospital beds, oxygen and ventilators coupled with low supply of vaccines, an effective strategy for vaccination is needed. Our study results provide a baseline data and supplement the evidence for the same. SARS CoV-2 Severe Acute Respiratory Virus Coronavirus-type 2 Health Care Worker AEFI Adverse Events Following Immunization Ig G Immunoglobulin Gamma . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 3, 2021. Consent for publication -Written informed consent was obtained from each participant prior to enrolment and blood sample draw. Data collected was compiled into excel sheets by SRV & AMR under the supervision of SJI. Data cleaning, analysis and review was done by SKN, UUG and PJ. The authors have no conflicts of interest associated with the material presented in this paper. SKN, AMR and PJ conceived and designed the study and developed the study protocol and analysis plan. SJI and JT coordinated the project. SKN, AMR, SRV and PJ coordinated data collection at the site. SKN, UUG and PJ analyzed the data. SKN and RB drafted the manuscript. All authors have reviewed the manuscript and approved it. PK, SJI and JT had complete access to the data and guarantee the manuscript. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 3, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 3, 2021. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 3, 2021. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 3, 2021. Figure 1 : Anti SARS Cov-2 Ig G antibody levels in individuals 28 days and 42 days after first dose of Covishield vaccine . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted July 3, 2021. ; https://doi.org/10.1101/2021.06.29.21259686 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted July 3, 2021. ; https://doi.org/10.1101/2021.06.29.21259686 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted July 3, 2021. ; https://doi.org/10.1101/2021.06.29.21259686 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted July 3, 2021. ; https://doi.org/10.1101/2021.06.29.21259686 doi: medRxiv preprint World Health Organization Covid-19 dashboard: www.covid19.who First COVID-19 Vaccines Receiving the US FDA and EMA Emergency Use Authorization. Discoveries Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials The Lancet Serosurveillance of SARS CoV 2 among the healthcare workers of a tertiary care teaching institution in Central Kerala during the post lockdown phase International Association for the Study of Obesity (IASO) and International Obesity Task Force (IOTF). The Asia-Pacific Perspective: Redefining Obesity and its Treatment. Geneva: World Health Organization SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates. The Lancet Analytical and clinical performances of five immunoassays for the detection of SARS-CoV-2 antibodies in comparison with neutralization activity Persistence of SARS-CoV-2-specific B and T cell responses in convalescent COVID-19 patients 6-8 months after the infection. Med (N Y) Persistence of serum and saliva antibody responses to SARS-CoV-2 spike antigens in COVID-19 patients. Sci Immunol Persistence of IgG response to SARS-CoV-2 The Lancet Infectious Diseases T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222trial. Nature medicine Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. The Lancet Antibody Response after First-dose of ChAdOx1-nCOV (Covishield) and BBV-152 (Covaxin) amongst Health Care Workers in India: Preliminary Results of Cross-sectional Coronavirus Vaccine-induced Antibody Titre (COVAT) study. medRxiv The Covishield vaccine induces robust immune response in Bangladeshi adults The authors would like to acknowledge the efforts of Dr Mimitha A M, Mr Anson Abraham, Mr Manoharan , Ms Manju , phlebotomists & technical staff from the central lab for the coordination ,sample collection at the vaccination centre, sample processing and storage .